Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

Teva completes Auspex buy, still pursuing Mylan

May 6, 2015
Life sciences
Teva has completed its $3.5-billion purchase of Auspex Pharmaceuticals, in a move the Israeli drugmaker says will enhance its revenue and earnings growth profile and strengthen its core central nervous system franchise.
 
The moves gives the firm access to Auspex’ lead investigational product SD-809 (deutetrabenazine), which is being developed for the potential treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Teva said it is expecting a US launch for the drug to treat Huntington’s sometime in 2016, if regulatory approval is granted.
 
According to chief executive Erez Vigodman, the combination of Auspex’ portfolio with Teva’s research and commercialisation capabilities “will unlock significant value” for shareholders.
 
Still hot for Mylan
Meanwhile, Teva remains intent on carrying through its proposed purchase of generics giant Mylan, despite the latter’s rejection of its $43 billion offer. 
 
The Jerusalem-headquartered group has now posted an updated investor presentation to its website, touting the benefits of the marriage. 
 
“Together with Mylan, we would have the infrastructure and the capabilities to more quickly pursue a differentiated business model that meets the evolving needs of patients and customers and support the highest levels of quality and clinical excellence,” said Vigodman, and reiterated his company’s commitment to the move.  
 
Mylan Q1 profit drop
Mylan, which itself is currently in hot pursuit of Dublin, Ireland-based group Perrigo, has just posted a substantial drop in first-quarter profit from $116 million, or $0.29 a share, to $56.6 million, or $0.13 a share, although this was largely because of acquisition costs.
 
Excluding these costs and other special items, earnings per share climbed from $0.66 to $0.70, as sales, despite taking a hit from currency effects, climbed $1.87 billion from $1.72 billion in the year-ago period.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach